Amiodarone and the Development of ARDS After Lung Surgery
To the Editor:
We read with interest the article by Van Mieghem et all and the editorial comment by Drs. Mathru and McDaniel,2 which were published in the June 1994 issue of Chest. In 1985, we reported our experience with intravenous amiodarone. We used a dose of 450 mg administered over 8 h in the treatment of ten patients who had uncontrolled malignant ventricular arrhythmias.3 This treatment was successful in all cases and four patients are still surviving. While amiodarone has a negative inotropic, chromotropic, and dromotropic effect, none of our patients developed ARDS at this dose, which was considerably lower than the dose used by Van Mieghem et al.' Their three cases of ARDS occurred in patients with total pneumonectomies rather than lobectomies, and in these patients the cardiac output remained constant. The single lung would therefore be exposed at least transiently to an even higher amount of a potentially toxic drug, and this may be a factor in the high rate of pulmonary complications. Amiodarone has been shown to control successfully atrial arrhythmias.4,5 In the cases presented, there were less instances of atrial arrhythmias in the treated patients. Lower doses of the intravenous drug or initiation of oral therapy before surgery may well prevent atrial arrhythmias and avoid the development of ARDS.
Our current method of using amiodarone in both ventricular and atrial arrhythmias is to give the patient an initial dosage of 400 mg and then 200 mg daily. If the arrhythmia recurs, then we give another increment of 400 mg daily on an as-needed-basis until the arrhythmia is controlled. We read with interest the article in the June 1994 issue of Chest by Van Mieghem and coworkers (Chest 1994; 105:1642-45) on the development of ARDS after pneumonectomy and the possible role of amiodarone in its cause.
In 1992, we reported in Intensive Care Medicinel about a patient who developed amiodarone pulmonary toxicity after pneumonectomy and who was treated with low-dose amiodarone 200 mg/d. In spite of this low dosage, amiodarone pulmonary toxicity (APT) developed in the patient 3 months after starting therapy with amiodarone, which required prolonged mechanical ventilation.
It was postulated that in the remaining lung in thin patients who have little adipose tissue, a drug concentrating effect might be involved causing APT and that dosages in case of pneumonectomy should be adapted to this particular situation. In the accompaning editorial,2 this was acknowledged as a possible new explanation for APT. It is possible that also the patients described in the study by Van Mieghem were thin but these data were not presented. On the other hand, the interval free period in our case was much longer than in the presented cases by Van Mieghem. This might be the consequence of the differences in initial loading strategy.
